BridgeMD
Prospective randomized study on sexual health and self-perceived quality of life (PROMs) in patients treated for cervical cancer
EU CTIS ID: 2025-521460-36-00
What this study is testing
To assess the improvement in sexual function and self-perceived quality of life using PROMs (Patient-Reported Outcomes) in patients treated for cervical cancer who undergo a multimodal intervention in the sexual sphere and lifestyle compared to those who undergo care within routine clinical practice.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Women of legal age
- Patients with primary cervical cancer stage FIGO I-III (initial or locally advanced) of squamous histology, adenocarcinoma or adenosquamous.
- Patients treated for cancer with surgery and/or radiotherapy ± systemic treatment in the Gynaecological Oncology Units of hospitals in Spain.
- Complete response after oncospecific treatment was obtained.
- Signature of the informed consent (IC) by the patient or responsible family member.
You likely can't join if
- Patients under 18 years of age
- Pregnancy or breastfeeding.
- Partial response after completion of oncospecific treatment.
- Patients with premalignant pathology.
- Diagnosis of a tumor of non-cervical origin or atypical histologies.
- Impossibility of completing the questionnaires included in the protocol autonomously.
See the full eligibility criteria
- Women of legal age
- Patients with primary cervical cancer stage FIGO I-III (initial or locally advanced) of squamous histology, adenocarcinoma or adenosquamous.
- Patients treated for cancer with surgery and/or radiotherapy ± systemic treatment in the Gynaecological Oncology Units of hospitals in Spain.
- Complete response after oncospecific treatment was obtained.
- Signature of the informed consent (IC) by the patient or responsible family member.
- Patients under 18 years of age
- Pregnancy or breastfeeding.
- Partial response after completion of oncospecific treatment.
- Patients with premalignant pathology.
- Diagnosis of a tumor of non-cervical origin or atypical histologies.
- Impossibility of completing the questionnaires included in the protocol autonomously.
- Contraindications to the use of vaginal estrogens.
- Patients undergoing fertility-sparing treatment (trachelectomy or conization).
- Patients undergoing palliative treatment.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.